"The agreement is not the end, but rather the beginning."

David Weitz, senior vice president, general counsel and chief intellectual property counsel with Takeda Pharmaceutical Co. Ltd., on the need for biotechs to execute on promises made during deal negotiations

"If you have a phone . . . and you're the only one on it, that's not really great."

George Church, professor of genetics at Harvard University, on the fact that even the best technologies are only as good as their reach

"We continue to believe that the FDA has every reason to reject Afrezza, and no reason to approve it."

Analyst Avik Roy, of Monness Crespi Hardt, speculating about the recent PDUFA delay for MannKind Corp.'s inhaled insulin drug Afrezza